BACKGROUND: Magnetic resonance imaging (MRI) may guide @entity0 surgery by measuring @entity41 size post-neoadjuvant chemotherapy (NAC). Accurate measurement may avoid overly radical surgery or reduce the need for repeat surgery. This individual @entity1 data (IPD) meta-analysis examines MRI's agreement with pathology in measuring the longest @entity5 diameter and compares MRI with alternative tests. METHODS: A systematic review of MEDLINE, EMBASE, PREMEDLINE, Database of Abstracts of Reviews of Effects, Heath Technology Assessment, and Cochrane databases identified eligible studies. Primary study authors supplied IPD in a template format constructed a priori. Mean differences (MDs) between tests and pathology (i.e. systematic bias) were calculated and pooled by the inverse variance method; limits of agreement (LOA) were estimated. Test measurements of 0.0  cm in the presence of pathologic @entity41 , and measurements >0.0  cm despite pathologic complete response (pCR) were described for MRI and alternative tests. RESULTS: Eight studies contributed IPD (N   =   300). The pooled @entity601 for MRI was 0.0  cm (LOA: +/-3.8  cm). Ultrasound underestimated pathologic size ( @entity601 : -0.3  cm) relative to MRI ( @entity601 : 0.1  cm), with comparable LOA. MDs were similar for MRI (0.1  cm) and mammography (0.0  cm), with wider LOA for mammography. Clinical examination underestimated size ( @entity601 : -0.8  cm) relative to MRI ( @entity601 : 0.0  cm), with wider LOA. @entity5 "missed" by MRI typically measured 2.0  cm or less at pathology; @entity5 >2.0  cm were more commonly "missed" by clinical examination (9.3  %). MRI measurements >5.0  cm occurred in 5.3  % of @entity1 with pCR, but were more frequent for mammography (46.2  %). CONCLUSIONS: There was no systematic bias in @entity5 measurement, but LOA are large enough to be clinically important. MRI's performance was generally superior to ultrasound, mammography, and clinical examination, and it may be considered the most appropriate test in this setting. Test combinations should be explored in future studies.

Agreement between MRI and pathologic XXXX size after neoadjuvant chemotherapy, and comparison with alternative tests: individual @entity1 data meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumors', 'MRI tumor', 'tumors'] @entity601 :: ('MESH:D009436', 'Disease') :: ['MD']
@entity0 :: (MESH:D001943,Disease) :: ['breast tumor']
